Clinical Trials
English, Greek

Get to Know Dr. Konstantinos Leventakos

Medical oncologist Dr. Konstantinos Leventakos is a fourth-generation physician whose love of medicine and caring for patients at the Mayo Clinic is deeply rooted.

His clinical focus revolves around the multidisciplinary care of thoracic malignancies such as mesothelioma, particularly lung cancer, pleural mesothelioma and neuroendocrine tumors.

As an assistant professor at the Mayo Clinic College of Medicine and Science, Leventakos is dedicated to the personalization of treatment and improving the efficiency of clinical practice.

He believes strongly in clinical trial research, serving as principal investigator of four studies at the Mayo Clinic aimed at improving lung cancer treatment at various levels.

Leventakos has a special interest in the integration of artificial intelligence for clinical trial matching and the development of novel immunotherapy to combat cancer.

Specialties of Dr. Konstantinos Leventakos

  • Pleural mesothelioma
  • Thymic malignancies
  • Small cell lung cancer
  • Non-small cell lung cancer
  • Neuroendocrine carcinoma
  • Palliative care
  • Artificial intelligence and clinical trial matching

Dr. Konstantinos Leventakos’ Experience and Medical Education

  • Mayo Clinic Minnesota
  • University of Athens Medical School (Ph.D.)
  • Georgetown University Hospital and Washington Hospital Center (Residency)
  • Attikon University Hospital, Athens (Residency)
  • University of Texas MD Anderson Cancer Center (Fellowship)
  • Medical School of University of Crete (M.D.)

Awards and Certifications

  • Board certified in medical oncology, hematology and internal medicine
  • Tow Shung Tan Humanism in Medicine Award

Publications of Dr. Konstantinos Leventakos

  • Murphy, S.J. et al. (2019, September). Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer. Journal of Thoracic Oncology.
  • Leventakos, K. et al. (2019, March 22). The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point. Current Treatment Options in Oncology.
  • Harris, F.R. et al. (2019, February). Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy. Molecular Oncology.
  • Leventakos, K. et al. (2017, September). Management of Multifocal Lung Cancer: Results of a Survey. Journal of Thoracic Oncology.